

28. **Blanchette VL, Imbach P, Andrew M, et al.** randomised trial of intravenous immune globulin G, intravenous anti-D and oral prednisone in acute immune thrombocytopenic purpura. *Lancet* 1994, 344: 703-7.
29. **Blanchette V, Bolton-Maggs P.** Childhood immune thrombocytopenic purpura ;Diagnosis and anagement. *Pediatr Clin N Amer* 2008, 55: 393-420.
30. **Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C.** Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. *J Pediatr* 2005, 147: 521-7.
31. **Salama A, Kiefel V, Amberg R, et al.** Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh_D). *Blut* 1984, 49:29-35.
32. **Scaradavou A, Wo B, Woloski BMR, et al.** Intravenous anti-D treatment of immune thrombocytopenic purpura:experience in 272 patients. *Blood* 1997, 89: 2689-700.
33. **Waro E, Zimmerman SA.** Anti-D; mechanism of action. *Seminars Hematol* 1998, 35 (suppl 1):14-22.
34. **Tarantino MD, Young G, Bertolone SJ, et al.** Single dose anti-D at 75 ug/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. *J Pediatr* 2006, 148: 489-94.
35. **Gaines AR.** Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho (D) immune globulin intravenous administration for immune thrombocytopenic purpura. *Blood* 2005, 106: 1532-7.
36. **Beardsley DS.** ITP in 21st Century. *Hematology* 2006, 11: 402-7.
37. **Ozsoylu S, Sayli TR, Ozturk G** Oral megadose methylpredisilone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. *Pediatr Hematol Oncol* 1993, 10: 317-21.
38. **van Hoff J, Ritchey AK.** Pulse methylprednisolone therapy for childhood idiopathic thrombocytopenic purpura. *J Pediatr* 1988, 113: 563-6
39. **Anderson JC.** Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. *N Eng J Med* 1994, 330: 1560-64.
40. **Chandra J, Dua T, Narayan S, Jain V, Sharma S, Dutta AK.** Dexamethasone therapy in chronic ITP. *Indian Pediatr* 2000, 37: 647-50.
41. **Borgana-Pignatti C, Rugolotto S, et al.** A trial of high dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in childhood. *J Pediatr* 1997, 130:13-16.
42. **Mazucconi MG, Fazi P, Bernasconi S, et al.** Therapy with high dexamethasone (HD-DXM) in previously untreated patients affected byidiopathic thrombocytopenic purpura: a GIMEMA experience. *Blood*, 2007, 109:1401-07.
43. **Garvey B.** Rituximab in the treatment of autoimmune haematological disorders. *Br J Haematol* 2008, 141: 149-69.
44. **Berentsen S.** Rituximab for the treatment of autoimmune cytopenias. *Hematologica* 2007, 92: 1589-96.
45. **Taylor RP, Lindorfer MA.** Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. *Nature, Clinical Practice, rheumatology* 2007, 3: 86-9.
46. **Sasi R, Delpoeta G, Stipa E, et al** Response to B cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. *Blood* 2007, 110: 2924-30.
47. **Taube T, Schmid A, Reinhard H, et al.** Effect of single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. *Haematologica* 2005, 90:281-3.
48. **Wang J, Wiley JM, Luddy R, et al.** Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. *J pediatr* 2005, 146: 217-21.
49. **Parodi E, Nobili B, Perrotta S, et al.** Rituximab (anti-CD 20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. *Inter J Hematol* 2006, 84: 48-53.
50. **Aledort LM, Hayward CP, Chen MG, et al** Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and relationship between platelet count, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. *Am J Hematol* 2004, 76:205-13.
51. **Koçak U, Gürsel T, Oztürk G.** The effect of steroid and intravenous immunoglobulin on thrombopoietin levels in pediatric patients with immune thrombocytopenic purpura. *Blood Coagul Fibrinolysis.* 2000, 11: 121-5
52. **Chang M, Nakagawa PA, Williams SA, et al.** Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryopoiesis in vitro. *Blood* 2002, 102: 887-895.
53. **Meabed MH, Taha GM, Mohamed SO, El-Hadidy KS** Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes. *Hematology.* 2007, 12: 301-7
54. **Solanilla A, Pasquet JM, Viallard JF, et al.** Platelet-associated CD154 in immune thrombocytopenic purpura. *Blood.* 2005, 105: 215-8.
55. **Nomura S, Dan K, Hotta T, et al .** Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. *Blood* 2002, 100: 728-30.
56. **Rice L, Nichol JL, McMillan R, et al.** Cyclic immune thrombocytopenia responsive to thrombopoietin growth factor therapy. *Am J Hematol* 2001, 68: 210-4.
57. **Li J, Yang C, Xia Y, et al.** Thrombocytopenia caused by development of antibodies to thrombopoietin. *Blood* 2001, 98: 3241-8.
58. **Kuter DJ.** New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. *Eur J Haematol Suppl.* 2008, 69: 9-18.
59. **Bussel JB, Kuter DJ, George JN, et al.** AMG 51, a thrombopoiesis-stimulating protein, for chronic ITP. *N Eng J Med* 2006, 355: 1672-81.
60. **Newland A, Caulier MT, Kappers-Klunne M, et al.** An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptidib, in patients with immune thrombocytopenic purpura. *Br J Haematol* 2006, 135: 547-553.
61. **Bussel JB, Chang G, Saleh Mn, et al.** Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. *N Eng J Med* 2007, 357: 2237-47.
62. **Wilde MI, Faulds D.** Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. *BioDrugs.* 1998, 10: 159-71.
63. **Bussel JB, Mukherjee R, Stone AJA** A pilot study of rHuIL-11 treatment of refractory ITP. *Am J Hematol.* 2001 Mar; 66(3): 172-7.
64. **Kuwana M, Nomura S, Fujimura K, et al.** Effect of single injection of humanized anti-CD154 monoclonal antibody on the platelet specific autoimmune response in patients with immune thrombocytopenic purpura. *Blood.* 2004 Feb 15; 103(4): 1229-36.
65. **Patel VL, Schwartz J, Bussel JB.** The effect of anti-CD40 ligand in immune thrombocytopenic purpura. *Br J Haematol* 2008, 141: 545-8.
66. **Chandra J, Yadav D.** ITP in children: Recent advances in treatment and future perspectives. In: *Manual on Idiopathic thrombocytopenic Purpura.* Sachdeva Anupam, Kalra Manas, Yadav SP(eds); New Delhi 2008.

ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH

The need for uniform ethical guidelines for research on human subjects is universally recognised. It has acquired a new sense of urgency as the critical issues in the area of biogenetic research involving human subjects have become acute. Apart from the mandatory clinical trails on new drugs, a number of diagnostic procedures, therapeutic interventions and prevention measures including the use of vaccines, are being introduced which involve human subjects. Further the advent of new medical devices and radio-active materials and therapeutic benefits of recombinant DNA products have added a new dimension to the ethical issues that need to be considered before evaluating these for their efficacy, utility and safety.

Any research using the human beings as subjects shall bear in

mind the following principles of : i) essentiality, (ii) voluntariness, informed consent, (iii) non exploitation, (iv) privacy and confidentiality, (v) precaution and risk minimisation, (vi) professional competence, (vii) accountability & transparency, (viii) maximisation of public interest and distributive justice (ix) institutional arrangements (x) public domain (xi) totality of responsibility and (xii) compliance.

Recent advances in the field of Assisted Reproductive technologies, organ transplantation, Human genome analysis, and gene therapy promise unquestionable benefits to mankind. At the same time, they raise many questions of law and ethics, stimulating public interest and concern.

(Source : ICMR Publication 2000)

MANUSCRIPT SUBMISSION : FOR JIMSA

Check-list

- (i) Copyright statement/declaration (not submitted or published elsewhere) signed by all the authors.
- (ii) Three hard copies of manuscript with illustrations attached to each; **must send an electronic copy of text with photographs loaded on CD.**
- (iii) **Title page :** Title of Manuscript, Name(s) and affiliation of author(s); Institution(s) and city(ies) address of corresponding author (Tel; Fax; e-mail)
- (iv) The text of the article should contain **Abstract** highlighting objectives, methods, results, conclusions.
- (v) Original Article(double-spaced on A-4 size paper): should contain introduction material & methods, results, discussion; **Indian Literature must be referred**, references numbered in text as they appear.
- (vi) Update/Review/ Therapy update should have appropriate headings. with reference numbers in the text; Indian Literature cited, wherever available.
- (vii) References: maximum number of references for update-30, original-20, Case reports-6:8.
- (viii) Each table on separate sheet; maximum number-4 in original article; 6 in update.
- (ix) Photographs/ figures in envelope, each marked figure number on reverse with legends on separate sheet, numbers not to exceed 4 in original, 2 in case report.
- (x) Statement signed by all authors regarding adherence to Standard ethical guidelines prescribed by ICMR 2000.